GWN323X
Total Payments
$1.9M
Transactions
24
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $215,708 | 5 | 0 |
| 2019 | $501,654 | 6 | 0 |
| 2018 | $656,658 | 8 | 3 |
| 2017 | $554,089 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 24 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I AND OR IB OPEN LABEL MULTI CENTER DOSE ESCLATION STUDY OF GWN323 ANTI GITR AS A SINGLE AGENT AND IN COMBINATION WITH PDR001 ANTI PD1 IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHONA | Novartis Pharmaceuticals Corporation | $1.9M | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $458.40 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.9M
- Total Doctors 3
- Transactions 24
About GWN323X
GWN323X is a drug associated with $1.9M in payments to 3 healthcare providers, recorded across 24 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $215,708 was paid across 5 transactions to 0 doctors.
The most common payment nature for GWN323X is "Unspecified" ($1.9M, 100.0% of total).
GWN323X is associated with 2 research studies, including "A PHASE I AND OR IB OPEN LABEL MULTI CENTER DOSE ESCLATION STUDY OF GWN323 ANTI GITR AS A SINGLE AGENT AND IN COMBINATION WITH PDR001 ANTI PD1 IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHONA" ($1.9M).